Related coverage linked through entity extraction aliases.
Jul 01, 2026
PureTech Health's IPF drug deupirfenidone received orphan drug designation from the FDA and European Commission. The designation provides market exclusivity and financial incentives. A phase 3 trial is expected to begin in the first half of 2026.
Mar 21, 2026
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
Feb 20, 2026
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
Feb 20, 2026
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
